Loading…
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $403M | $64M | $-23M | $-13M | 7.5% | 21.3% | -56.2% |
| 2024 | $332M | $8M | $-52M | $-24M | 13.3% | 185.7% | -75.3% |
| 2023 | $116M | $-150M | $-209M | $-135M | 46.0% | 54.1% | -10.4% |
| 2022 | $75M | $-176M | $-234M | $-175M | 72.2% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 75.47 | 116.33 | 332.31 | 403.14 |
| Operating Revenue | - | 75.47 | 116.33 | 332.31 | 403.14 |
| Cost Of Revenue | - | 26.97 | 43.27 | 68.60 | 129.22 |
| Gross Profit | - | 48.51 | 73.07 | 263.71 | 273.91 |
| Operating Expense | - | 228.01 | 228.63 | 209.31 | 213.64 |
| Research And Development | - | 118.93 | 86.11 | 46.24 | 47.85 |
| Selling General And Administration | - | 109.08 | 142.52 | 163.07 | 165.79 |
| Total Expenses | - | 254.98 | 271.90 | 277.91 | 342.86 |
| Operating Income | - | -179.50 | -155.56 | 54.40 | 60.27 |
| Total Operating Income As Reported | - | -179.50 | -155.56 | 54.40 | 60.27 |
| EBITDA | - | -176.35 | -150.11 | 7.57 | 63.87 |
| Normalized EBITDA | - | -176.35 | -150.11 | 62.49 | 63.87 |
| EBIT | - | -176.85 | -150.27 | 7.51 | 63.76 |
| Interest Expense | - | 56.81 | 58.98 | 59.25 | 84.60 |
| Net Interest Income | - | -56.81 | -58.98 | -59.25 | -84.60 |
| Other Non Operating Income Expenses | - | 2.65 | 5.29 | 8.02 | 3.49 |
| Other Income Expense | - | 2.65 | 5.29 | -46.90 | 3.49 |
| Interest Expense Non Operating | - | 56.81 | 58.98 | 59.25 | 84.60 |
| Net Non Operating Interest Income Expense | - | -56.81 | -58.98 | -59.25 | -84.60 |
| Pretax Income | - | -233.66 | -209.25 | -51.74 | -20.84 |
| Tax Provision | - | - | 0 | 0 | 1.84 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income From Continuing And Discontinued Operation | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income From Continuing Operation Net Minority Interest | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income Common Stockholders | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Net Income Including Noncontrolling Interests | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Normalized Income | - | -233.66 | -209.25 | 3.17 | -22.68 |
| Diluted NI Availto Com Stockholders | - | -233.66 | -209.25 | -51.74 | -22.68 |
| Basic Average Shares | - | 66.41 | 103.11 | 187.18 | 207.87 |
| Diluted Average Shares | - | 66.41 | 103.11 | 187.18 | 207.87 |
| Reconciled Depreciation | - | 0.50 | 0.16 | 0.06 | 0.10 |
| Reconciled Cost Of Revenue | - | 26.97 | 43.27 | 68.60 | 129.22 |
| Total Unusual Items | - | 0 | 0 | -54.92 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -54.92 | 0 |
| Special Income Charges | - | 0 | 0 | -54.92 | 0 |
| Other Special Charges | - | - | - | 54.92 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc.this co. | ESPR | $806M | - | - | 7.5% | 13.94 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| LB Pharmaceuticals Inc | LBRX | $829M | -32.88 | 2.75 | -8.4% | -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA |
| - |
| - |
| - |
| - |
| - |
| - |
| $824M |
| -3.37 |
| 5.12 |
| -151.8% |
| -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Peer Median | - | -4.98 | 2.06 | -13.0% | -3.81 | |